US1920032000 - Common Stock
TELESIS BIO INC
NASDAQ:TBIO (9/27/2024, 8:22:41 PM)
After market: 2.85 -0.38 (-11.76%)3.23
-0.76 (-19.05%)
Telesis Bio Inc is a US-based company operating in Life Sciences Tools & Services industry. The company is headquartered in San Diego, California and currently employs 137 full-time employees. The company went IPO on 2021-06-18. Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The firm provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.
TELESIS BIO INC
10431 Wateridge Circle, Suite 150
San Diego CALIFORNIA 02421
P: 18582284115
CEO: Ronald C. Renaud Jr.
Employees: 137
Website: https://telesisbio.com/
Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities
Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities...
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO) (“Telesis” or the “Company”), a leading provider of RNA and DNA solutions...
Here you can normally see the latest stock twits on TBIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: